In patients with breast cancer, 3 (50%) phosphatidylinositol-3-kinase (PI3K) (PIK3CA) actionable mutations were found, and ESR1 actionable mutations were present in 1 (16.67%) patient. This evidence concerns the gene ESR1 and breast carcinoma.